<DOC>
	<DOC>NCT01101334</DOC>
	<brief_summary>This is a Phase 2 and open-label (subject will know the treatment he or she is receiving) study. The subject will receive either Erlotinib alone or Erlotinib + CS-7017 in this study. The study will determine what effect adding CS-7017 to Erlotinib has on safety and length of survival in subjects with advanced non-small cell lung cancer who failed the first treatment.</brief_summary>
	<brief_title>Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Efatutazone</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically or cytologically confirmed stage IIIB or IV NSCLC. Recurrent disease (either no response to treatment or subsequent relapse after an objective response) that has progressed after first line therapy. Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 criteria. ≥ 18 years of age. ECOG performance status of 0, 1, or 2. Adequate organ and bone marrow function. Resolution of any toxic effects of prior therapy (except alopecia) to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0 grade ≤ 1. Agreement to use effective contraception while on treatment and for at least 3 months after end of treatment. No treatment with anticancer therapy within 4 weeks before study treatment. No therapeutic or palliative radiation therapy or major surgery within 4 weeks before study treatment (except for radiotherapy for brain metastases). No administration of other thiazolidinediones (TZDs) within 4 weeks before study treatment. No current need for concomitant use of other TZDs during the study. No uncontrolled infection requiring IV antibiotics, antivirals, or antifungals, known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection at time of screening. No history of any of the following conditions within 6 months before initiating study treatment: diabetes mellitus requiring treatment with insulin or TZD agents; myocardial infarction with significant impairment of cardiac function; severe/unstable angina pectoris; coronary/peripheral artery bypass graft; New York Heart Association (NYHA) class III or IV congestive heart failure; malabsorption syndrome, chronic diarrhea (lasting &gt; 4 weeks), inflammatory bowel disease, or partial bowel obstruction. No pericardial or pleural effusion (eg, requiring drainage) or pericardial involvement with the tumor. Subjects with minimal pleural effusion may be eligible upon request by Investigator and approval by Sponsor. Neither pregnant nor breast feeding. No known EGFR mutations.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>NSCLC</keyword>
</DOC>